XML 50 R14.htm IDEA: XBRL DOCUMENT
v3.21.2

Other current and non-current assets | 12 Months Ended
--- | ---
Dec. 31, 2020
Text Block [Abstract] |
Disclosure of other assets [text block] |
8. | Other current and non-current assets
Other current assets
|  | As of |
|  | December 31, 2020 |  |  | December 31, 2019 |
|  | (Euros in thousands) |
Grant receivable |  |  | 875 |  |  |  | 998 |
Prepaid expenses |  |  | 2,389 |  |  |  | 1,236 |
Positive market value forward contract |  |  | 914 |  |  |  | — |
Value added tax receivable |  |  | 798 |  |  |  | 768 |
Capitalized transaction costs |  |  | — |  |  |  | 48 |
Other assets |  |  | 787 |  |  |  | 617 |
Other current assets |  |  | 5,763 |  |  |  | 3,667 |
The Group recognizes receivables for government grants when it is reasonably assured that the grant will be received, and all contractual conditions have been complied with. As of December 31, 2020, and 2019, no receivables were considered impaired. Prepaid expenses include prepaid insurance expenses of €1.0 million and €0.1 million as of December 31, 2020 and 2019, respectively. The Group paid €0.5 million and €0.6 million of incremental cost for the successful arrangement of the Celgene Switzerland LLC (“BMS”) and Genmab A/S (“Genmab”) collaboration agreements as of December 31, 2020 and 2019, respectively. Additionally, prepaid expenses include expenses for licenses and software of €0.6 million and €0.2 million as of December 31, 2020 and 2019, respectively. The remaining amount is related to prepaid maintenance expenses. Other assets include receivables from capital gains tax of €0.4 million and €0.3 million as of December 31, 2020 and 2019, respectively. The remaining amount is related to prepaid deposit expenses. Other non-current assets
|  | As of |
|  | December 31, 2020 |  |  | December 31, 2019 |
|  | (Euros in thousands) |
Prepaid expenses |  |  | 724 |  |  |  | 937 |
Other non-current assets |  |  | — |  |  |  | 325 |
Total non-current assets |  |  | 724 |  |  |  | 1,262 |
Prepaid expenses consist of €0.7 million and €0.9 million of incremental cost paid for the successful arrangement of the BMS and Genmab collaboration agreements as of December 31, 2020 and 2019, respectively.

X
- Definition The disclosure of other assets. [Refer: Other assets] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfOtherAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block. + References No definition available. + Details
Name: | imtx_TextBlockAbstract
Namespace Prefix: | imtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration